Baird Reiterates Buy Rating on RGNX
Baird maintains its buy rating on RGNX with a $32 price target, a 310.26% upside from the current price.
Key Points
- Baird reiterated a buy rating on RGNX with a $32 price target on June 22, 2026.
- Baird's $32 price target implies 310.26% upside from REGENXBIO Inc.'s ($RGNX) current $7.80 share price.
- RGNX shares traded at $7.80 on Monday amid insider buying activity.
- BlackRock and State Street adjusted their RGNX positions, while Vanguard opened a new stake.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 22, 2026, Baird analyst Brian Skorney reiterated his buy rating on RGNX, maintaining a price target of $32. This comes as the stock traded at approximately $7.80 on Monday.
Baird vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in RGNX
BlackRock, Inc. grew its holdings by 25,997 shares, bringing its total to about 5.78 million shares valued at $48.46 million. State Street Corp significantly increased its position by 444,749 shares to a total of 2.73 million shares, worth around $22.89 million. Meanwhile, JPMorgan Chase & Co reduced its holdings by 69,702 shares, leaving it with 3.48 million shares valued at $27.07 million. Morgan Stanley added 51,369 shares, ending with 2.07 million shares valued at $17.31 million. Vanguard Capital Management LLC opened a new position with approximately 2 million shares valued at $16.82 million.
REGENXBIO Inc. Stock Down 19.3%
Shares of RGNX traded near $7.80 on Monday. While specific market cap and P/E ratio data are not provided, the stock has seen recent activity from both institutional investors and analysts.
$RGNX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at REGENXBIO Inc.
Several insiders made notable buys on May 29, 2026. Daniel Tasse, Kenneth Mills, and David Stump each acquired 46,600 shares. Additionally, Kenneth Mills, Allan Fox, and Alexandra Glucksmann each purchased 9,807 shares. These transactions were not part of planned trading programs.
Analysts Set New Price Targets
On June 22, 2026, Baird maintained its buy rating with a $32 price target. Leerink Partners also maintained a buy rating, setting a target of $18. Earlier in June, HC Wainwright & Co. reiterated its buy rating with a $26 target on June 5. The consensus among analysts is bullish, with a strong buy recommendation and a mean price target reflecting optimism for RGNX's prospects.
Bottom Line
Baird's reaffirmation of its buy rating with a $32 target reflects continued confidence in RGNX. While the stock traded at $7.80 recently, insider buying and institutional adjustments indicate active interest. As with all 13F filings and analyst ratings, these insights are backward-looking and serve as a snapshot of sentiment at the time.
Get REGENXBIO Inc. alerts
New 13F filings, insider trades, and analyst moves on $RGNX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.